W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial.

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Taking Wegovy (semaglutide) can be a powerful step towards achieving weight loss goals and improving overall health—especially when done in conjunction with lifestyle changes, such as following ...